Observations placeholder

Zileuton (trade name ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation. Zileuton is used for the maintenance treatment of asthma. and is now marketed in two formulations under the brand names ZYFLO and ZYFLO CR. The original immediate-release formulation of zileuton, known as ZYFLO, is taken four times per day. The extended-release formulation, ZYFLO CR, is taken twice daily.

Although the 600 mg immediate release tablet (Zyflo) and extended release formulation of zileuton is still available (Zyflo CR), the 300 mg immediate release tablet was withdrawn from the U.S. market on February 12, 2008

Adverse effects

The most common adverse reactions reported by patients treated with ZYFLO CR were sinusitis (6.5%), nausea (5%), and pharyngolaryngeal pain (5%) vs. placebo, 4%, 1.5%, and 4% respectively.

On Feb, 25, 2016: 503 people reported to have side effects when taking Zyflo. Among them, 1 people (0.20%) has Hallucination.

Time on Zyflo when people have Hallucination  :

On Jan, 28, 2016: 503 people reported to have side effects when taking Zyflo. Among them, 6 people (1.19%) have Death.

Time on Zyflo when people have Death  :

 On Feb, 25, 2016: 80 people reported to have side effects when taking Zyflo cr. Among them, 3 people (3.75%) have Death.

Time on Zyflo cr when people have Death  :